No Data
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
BioVie | 10-Q: Q1 2025 Earnings Report
Express News | BioVie Inc - Pd-202 Trial Expected to Start Early 2025, Results by Late 2025
Express News | Biovie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
(BIVI) - Analyzing BioVie's Short Interest
Express News | BioVie Inc - Prices Direct Offering of 1,146,000 Shares at $2.83 Each
No Data
No Data